CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Rhea-AI Summary
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2024. Dr. John Alam, CEO of CervoMed, will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications' at 8:00am ET.
The conference provides CervoMed with a platform to engage with investors through one-on-one meetings, potentially increasing visibility for the company's innovative approach to addressing age-related neurologic disorders. This event offers an opportunity for CervoMed to showcase its progress and strategy in pursuing significant market opportunities within the healthcare sector.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRVO declined 4.80%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John Alam, Chief Executive Officer, is scheduled to participate in a panel discussion and one-on-one investor meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, being held in New York, NY, on October 9, 2024.
Panel Details
Title: “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
Date: Wednesday, October 9, 2024
Time: 8:00am ET
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) participating in the ROTH Healthcare Opportunities Conference?
What panel is CervoMed's CEO participating in at the ROTH conference?
What is the focus of CervoMed's (CRVO) clinical research?
Will CervoMed (CRVO) be conducting investor meetings at the ROTH conference?
